Telix Pharmaceuticals completes enrolment for glioblastoma trial
Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.
Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.
Jim Chalmers will deploy fresh Treasury analysis to quell an investor outcry over federal budget changes to capital gains tax.
Mineral Resources (ASX:MIN) is set to dust off its mothballed Bald Hill lithium mine in the Goldfields, triggering a recruitment drive.
Federal budget trust tax hikes are forcing 350,000 Australian small businesses to restructure, triggering a massive state stamp duty crisis.
Bally’s Corp. (NYSE:BALY) reported a 28.3% surge in first-quarter revenue, hitting $755.7 million for the period ended March 31, 2026.
Agilysys (NASDAQ:AGYS) reported its financial results for the fiscal 2026 fourth quarter ended March 31, 2026, securing its 17th consecutive quarter of record-breaking top-line results.
CBAK Energy Technology (NASDAQ:CBAT) reported its unaudited financial results for the first quarter ended March 31, 2026, delivering an explosive near-doubling of its top-line revenue.
Ryanair Holdings plc (NASDAQ:RYAAY) reported its finalized, record-breaking financial results for the fiscal year ended March 31, 2026 (FY26), highlighting explosive bottom-line performance, strategic fuel defenses, and significant corporate restructuring.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) announced positive chemistry, manufacturing, and controls (CMC) data supporting the late-stage development of its lead antimicrobial candidate, Nu-3.
C3is (NASDAQ:CISS) announced its financial and operational results for the first quarter ended March 31, 2026, delivering substantial bottom-line expansion and enhanced operating leverage.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy
